Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Sales (2020 - 2025)

Ovid Therapeutics' Return on Sales history spans 6 years, with the latest figure at 13.46% for Q4 2025.

  • For Q4 2025, Return on Sales rose 6740.0% year-over-year to 13.46%; the TTM value through Dec 2025 reached 2.4%, up 5154.0%, while the annual FY2025 figure was 2.4%, 4430.0% up from the prior year.
  • Return on Sales reached 13.46% in Q4 2025 per OVID's latest filing, up from 92.11% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 50.42% in Q2 2024 to a low of 1077.98% in Q3 2022.
  • Average Return on Sales over 5 years is 94.36%, with a median of 9.32% recorded in 2022.
  • Peak YoY movement for Return on Sales: crashed -107858bps in 2022, then surged 97474bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.12% in 2021, then soared by 56bps to 0.05% in 2022, then crashed by -33bps to 0.07% in 2023, then tumbled by -78339bps to 53.94% in 2024, then surged by 125bps to 13.46% in 2025.
  • Per Business Quant, the three most recent readings for OVID's Return on Sales are 13.46% (Q4 2025), 92.11% (Q3 2025), and 0.75% (Q2 2025).